Session Details

Session Details

03:45 PM - 05:30 PM - Room 339-342

M. Paulina Velasquez - MD - St Jude Children's Research Hospital

Co-Chair

03:45 PM - 05:30 PM - Room 339-342

Agnieszka Czechowicz - MD, PhD - Stanford School of Medicine

Co-Chair

03:45 PM - 04:00 PM - Room 339-342

Phoebe Duong - PharmD - University of Colorado, Anschutz Medical Campus

136: Logic Gated CAR T Cells Targeting Acute Myeloid Leukemia Effectively Clear Leukemia While Mitigating Skin and Neuronal Toxicity

04:00 PM - 04:15 PM - Room 339-342

Quenton Bubb - MPhil - Stanford University

137: Development of Extracellularly Linked Concatemeric Trivalent Cytokine (ELeCTriC) Chimeric Antigen Receptor (CAR) T-Cells as Dual Conditioning and Immunotherapeutic Agents

04:15 PM - 04:30 PM - Room 339-342

Shannon Oda - Ph.D. - Seattle Children's Research Institute

138: Developing Adoptive Cell Therapy Strategies to Leverage Myeloid Immunity Against AML

04:30 PM - 04:45 PM - Room 339-342

Richard Vile - PhD - Mayo Clinic

139: Ex Vivo and In Vivo Generation of Dual Specific CAR T Cells for Combination CAR T/Oncolytic Virus Therapy

04:45 PM - 05:00 PM - Room 339-342

Dina Schneider - Lentigen Technology, Inc., a Miltenyi Biotec Company

140: ROR1 CAR Armored with Dominant Negative TGF-Beta Receptor II Demonstrates Enhanced Efficacy in Xenograft Models of Pancreatic Cancer

05:00 PM - 05:15 PM - Room 339-342

Victor Lu - Innovative Cellular Therapeutics

141: A Phase 1 Dose Escalation Study of a Novel Coupled CAR T Cell Therapy, GCC19CART, for Patients with Metastatic Colorectal Cancer

05:15 PM - 05:30 PM - Room 339-342

Gloria Pezzella - Childrens National Hospital

142: Targeting AML with Multi-Antigen Specific T Cells Engineered to Express a CAR Specific for SSX2 Peptide 41-49